BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biliary tract cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for biliary tract cancer: 95 (67 sponsors; 13 newly posted in the last 180 days, 1 stopped in the last 180 days; 9 new-entrant sponsors). Momentum score 13.2, rank 53 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 20, Phase 2 53, Phase 3 15, Phase 4 2, N/A 5.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN14P2 7, P3 5, NA 202
Sichuan Baili Pharmaceutical Co., Ltd.3P2 1, P3 211
Suzhou Suncadia Biopharmaceuticals Co., Ltd.4P2 3, P3 101
Akeso2P2 1, P3 101
Taiho Pharmaceutical Co., Ltd.2P3 1, P1 110
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1P3 101
Compass Therapeutics COMP1P3 100
InnoPharmax Inc.1P3 100
J-Pharma Co., Ltd.1P3 100
Jazz Pharmaceuticals JAZZ1P3 100
Merck Sharp & Dohme LLC MRK3P4 1, P2 211
AbbVie ABBV2P1 210
Amgen AMGN2P2 1, P1 101
Eli Lilly and Company LLY2P2 201
Seagen, a wholly owned subsidiary of Pfizer2P2 200
SystImmune Inc.2P1 201
Yuhan Corporation2P2 200
3D Medicines (Sichuan) Co., Ltd.1P2 100
AccSalus Biosciences, Inc.1P1 100
Actithera INC. new entrant1P2 110
Astellas Pharma Global Development, Inc.1P2 101
Avenzo Therapeutics, Inc.1P2 100
Bayer1P2 100
Beijing Biostar Pharmaceuticals Co., Ltd.1P2 101
Beijing Biotech new entrant1P2 111

New-entrant sponsors: Actithera INC., Beijing Biotech.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Taiho Oncology, Inc.NCT05727176 Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementAdvanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangementrecruiting120
2026-12 est.P1/P2TiumBio Co., Ltd.NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsSolid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancerrecruiting140
2026-12 est.P3TransThera Sciences (Nanjing), Inc.NCT05948475 Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaCholangiocarcinomaactive not recruiting200
2026-12 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05987358 A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.Biliary Carcinomaactive not recruiting165
2026-12-17 est.P3IpsenNCT06730061 A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)Primary Biliary Cholangitisactive not recruiting18
2026-12-30 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerBiliary Tract Canceractive not recruiting93
2026-12-30 est.P1/P2Astellas Pharma Global Development, Inc.NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metastaactive not recruiting240
2026-12-31 est.P2Jiangsu HengRui Medicine Co., Ltd.NCT06413745 Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract CanHER2 Expression / Amplification in Patients With Biliary Tract Canceractive not recruiting59
2026-12-31 est.P2Shanghai Pharmaceuticals Holding Co., LtdNCT06434597 A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.Biliary Tract or Colorectal Cancer With Her2-positive/Mutatedrecruiting60
2026-12-31 est.P2Valenta Pharm JSCNCT06842966 Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary DyskinesiaChronic Cholecystitis; Biliary Dyskinesiarecruiting300
2027-01 est.P2Mirum Pharmaceuticals, Inc. MIRMNCT05050136 A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisPrimary Biliary Cholangitis; PBCactive not recruiting333

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-17 est.P2AstraZeneca AZNNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcirecruiting226
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-28 est.P3Albireo, an Ipsen CompanyNCT05426733 An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaBiliary Atresiaactive not recruiting180
2026-10-27 est.P2AstraZeneca AZNNCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma; Biliary Tract Canceractive not recruiting294
2026-10 est.P2Qilu Pharmaceutical Co., Ltd.NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerCLDN18.2-positive Advanced Biliary Tract Cancernot yet recruiting120
2026-10 est.P3AkesoNCT06591520 AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerBiliary Tract Canceractive not recruiting682
2026-09-09P1/P2Umecrine Cognition ABNCT07304843 A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and CognitivePrimary Biliary Cholangitis (PBC)completed207
2026-06-22P3Albireo, an Ipsen CompanyNCT04336722 Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)Biliary Atresiacompleted254
2026-06-16P3IpsenNCT06383403 A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.Primary Biliary Cholangitiscompleted92

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "biliary tract cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.